Literature DB >> 12160940

Mitochondrial K(ATP) channels: role in cardioprotection.

Olaf Oldenburg1, Michael V Cohen, Derek M Yellon, James M Downey.   

Abstract

The role of the mitochondrial ATP-sensitive potassium channel (mK(ATP)) in ischemic preconditioning and cardioprotection is reviewed. A great deal of accumulated evidence implicatese opening of this channel as an important step in the anti-infarct effect of ischemic preconditioning. Recent studies, however, reveal that channel opening can actually serve as a signal transduction element. Data indicate that mK(ATP) opening causes mitochondria to generate reactive oxygen species (ROS) which then activate downstream kinases. Opening of mK(ATP) prior to ischemia can serve as a trigger since the critical time for its opening is prior to the onset of the lethal ischemic insult. Most G(i)-coupled receptors trigger protection through the mK(ATP)/ROS pathway except for the adenosine receptor which uses some other, as yet unidentified, pathway. Possible coupling schemes between the receptors and the mK(ATP) are discussed. Protection from preconditioning can also be aborted when a mK(ATP) blocker is present only during the lethal ischemic insult (mediator phase), but a much higher concentration of the blocker is required. Thus the mK(ATP) probably serves a dual role as both a trigger and a mediator. Possible end-effectors of preconditioning's protection are discussed including the mK(ATP) itself.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160940     DOI: 10.1016/s0008-6363(02)00439-x

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  40 in total

Review 1.  Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning.

Authors:  Michael Zaugg; Marcus C Schaub
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

2.  Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs.

Authors:  Rainer Schulz; Petra Gres; Gerd Heusch
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 3.  Physiology of potassium channels in the inner membrane of mitochondria.

Authors:  Ildikò Szabò; Luigi Leanza; Erich Gulbins; Mario Zoratti
Journal:  Pflugers Arch       Date:  2011-11-18       Impact factor: 3.657

4.  gp-91 mediates histone deacetylase inhibition-induced cardioprotection.

Authors:  Ting C Zhao; Ling X Zhang; Guangmao Cheng; Jun T Liu
Journal:  Biochim Biophys Acta       Date:  2010-04-28

5.  Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways.

Authors:  Yeshi Hu; Xin Chen; Ting-Ting Pan; Kay Li Neo; Shiau Wei Lee; Ester Sandar Win Khin; Philip K Moore; Jin-Song Bian
Journal:  Pflugers Arch       Date:  2007-08-01       Impact factor: 3.657

Review 6.  Mitochondrial signaling pathways: a receiver/integrator organelle.

Authors:  Michael J Goldenthal; José Marín-García
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

Review 7.  Mitochondrial K(ATP) channels in cell survival and death.

Authors:  Hossein Ardehali; Brian O'Rourke
Journal:  J Mol Cell Cardiol       Date:  2005-02-19       Impact factor: 5.000

8.  Targeted expression of Kir6.2 in mitochondria confers protection against hypoxic stress.

Authors:  Marko Ljubkovic; Jasna Marinovic; Andreas Fuchs; Zeljko J Bosnjak; Martin Bienengraeber
Journal:  J Physiol       Date:  2006-09-07       Impact factor: 5.182

Review 9.  Mitochondria and cardioprotection.

Authors:  Fabio Di Lisa; Marcella Canton; Roberta Menabò; Nina Kaludercic; Paolo Bernardi
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

10.  The antiarrhythmic effect of centrally administered rilmenidine involves muscarinic receptors, protein kinase C and mitochondrial signalling pathways.

Authors:  M Iwasaki; Y Hayashi; T Kamibayashi; A Yamatodani; T Mashimo
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.